LEMMAbTM (Linker Enhanced Mono-chained Multi-specific Antibody) is our proprietary technology platform that uses natural IgG with Fc in constructing bispecific or multi-specific antibody for cutting-edge biomedical research and development. Owing to the single chain and symmetrical nature, LEMMAbTM antibodies resulting from this technology are free of mismatches, more soluble, less prone to aggregate, simpler to purify, and expressed in higher yield. These types of antibodies tend to have decreased immunogenicity and improved binding affinity, safety profiles, and developability.